Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Nov 15.

Published in final edited form as: Toxicol Appl Pharmacol. 2017 Sep 21;335:16–27. doi: 10.1016/j.taap.2017.09.017

(A) Effects of gefitinib+LMB treatment on the protein expression of EGFR, p-EGFR(Tyr1068), Akt, p-Akt(Ser473), Erk1/2, p-Erk1/2(Thr202/Tyr204), survivin, and p21. After 48 hrs treatment, cells were harvested for Western blot analysis to determine protein levels. Blots were also probed for α-tubulin to confirm equal protein loading. (B) The relative protein intensities of p-EGFR(Tyr1068), p-Akt(Ser473), p-Erk1/2(Thr202/Tyr204), survivin, and p21 as compared to the control after normalized by the intensity of α-tubulin. The intensity of each band was quantified using ImageJ software. Data are means±SD, n= 3. Mean values of the same protein containing different letters indicates a significant difference among the treatment groups analyzed by a one-way ANOVA followed by a Fisher’s LSD test (p<0.05). Values bearing the letter “a” indicate no significant differences compared with control, those labeled “b” denote a significant difference when compared with the control, and “c” denotes a significant difference when gefitinib+LMB is compared with gefitinib alone. LMB: 0.5 nM LMB, Gefitinib12: 12 μM gefitinib, and Gefitinib24: 24 μM gefitinib.

(A) Effects of gefitinib+LMB treatment on the protein expression of EGFR, p-EGFR(Tyr1068), Akt, p-Akt(Ser473), Erk1/2, p-Erk1/2(Thr202/Tyr204), survivin, and p21. After 48 hrs treatment, cells were harvested for Western blot analysis to determine protein levels. Blots were also probed for α-tubulin to confirm equal protein loading. (B) The relative protein intensities of p-EGFR(Tyr1068), p-Akt(Ser473), p-Erk1/2(Thr202/Tyr204), survivin, and p21 as compared to the control after normalized by the intensity of α-tubulin. The intensity of each band was quantified using ImageJ software. Data are means±SD, n= 3. Mean values of the same protein containing different letters indicates a significant difference among the treatment groups analyzed by a one-way ANOVA followed by a Fisher’s LSD test (p<0.05). Values bearing the letter “a” indicate no significant differences compared with control, those labeled “b” denote a significant difference when compared with the control, and “c” denotes a significant difference when gefitinib+LMB is compared with gefitinib alone. LMB: 0.5 nM LMB, Gefitinib12: 12 μM gefitinib, and Gefitinib24: 24 μM gefitinib.